Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960955 | 0.93 | HDAC3 (0.59) | HDAC3HDAC1HDAC2KCNH2 | |
| SCHEMBL21275921 | 0.91 | HDAC3 (0.62) | HDAC3GBA1MEN1MAPTTSHR | |
| SCHEMBL23961022 | 0.88 | BACE1 (0.51) | HDAC3MEN1MAPTTSHRKMT2A | |
| SCHEMBL20181695 | 0.86 | HDAC3 (0.57) | HDAC3GBA1HDAC1HDAC2KCNH2 | |
| SCHEMBL20163102 | 0.85 | MAPK8 (0.45) | HDAC3GBA1HDAC1HDAC2KCNH2 | |
| SCHEMBL20181689 | 0.85 | HDAC2 (0.62) | HDAC3HDAC1HDAC2KCNH2 | |
| SCHEMBL20181717 | 0.85 | HDAC3 (0.63) | HDAC3GBA1MEN1MAPTTSHR | |
| SCHEMBL19278386 | 0.85 | HDAC3 (0.51) | HDAC3GBA1MEN1MAPTTSHR | |
| SCHEMBL20181817 | 0.85 | GBA1 (0.47) | HDAC3GBA1HDAC1HDAC2KCNH2 | |
| SCHEMBL23961031 | 0.85 | HDAC3 (0.62) | HDAC3HDAC1HDAC2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC3 7/4885GBA1 1706/4885MEN1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.